I doubt there is any buyout, but even if there was, it needs to be realistic and the worth of NGIO is only around 600 million without the Vaccine work, so adding the China Malaysia deals, it would be worth about 3 billion tops. Generex with everything else in the long run would probably be worth say another billion tops with Excellegan, ownership in NGIO, clinics and possible diabetes work in the future if anything happens with that.

So, let's say 4 billion all together. 46 billion is a pipe dream for years to come unless a ton of viruses all of the sudden pop up.

Of course the AE37 is a big question mark....